{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:31Z","timestamp":1791994591944,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["111-2320-B-039 -016 -MY3"],"award-info":[{"award-number":["111-2320-B-039 -016 -MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital Health System","doi-asserted-by":"publisher","award":["DMR-113-016"],"award-info":[{"award-number":["DMR-113-016"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital Health System","doi-asserted-by":"publisher","award":["DMR-111-034"],"award-info":[{"award-number":["DMR-111-034"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Journal"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bj.2026.101002","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:36:48Z","timestamp":1781105808000},"page":"101002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["PRMT5-mediated methylation of LKB1 controls PD-L1 expression in NSCLC"],"prefix":"10.1016","author":[{"given":"Yi-Cheng","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khuong T.L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Ju","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Mao","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ling","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-8716","authenticated-orcid":false,"given":"Wei-Chien","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yen","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bj.2026.101002_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bj.2026.101002_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2024.102693","article-title":"Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN","volume":"93","author":"Zhou","year":"2024","journal-title":"Cancer Epidemiol"},{"issue":"12","key":"10.1016\/j.bj.2026.101002_bib3","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bj.2026.101002_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.761042","article-title":"\"How Long Have I Got?\" in Stage IV NSCLC Patients With at Least 3 Months Up to 10 Years Survival, Accuracy of Long-, Intermediate-, and Short-Term Survival Prediction Is Not Good Enough to Answer This Question","volume":"11","author":"Guo","year":"2021","journal-title":"Front Oncol"},{"issue":"14","key":"10.1016\/j.bj.2026.101002_bib5","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2026.101002_bib6","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.2147\/DDDT.S267433","article-title":"Research Status and Outlook of PD-1\/PD-L1 Inhibitors for Cancer Therapy","volume":"14","author":"Ai","year":"2020","journal-title":"Drug Des Devel Ther"},{"issue":"19","key":"10.1016\/j.bj.2026.101002_bib7","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.bj.2026.101002_bib8","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"10066","key":"10.1016\/j.bj.2026.101002_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"28","key":"10.1016\/j.bj.2026.101002_bib10","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-Year Overall Survival for Patients With Advanced Non\u2012Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bj.2026.101002_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106214","article-title":"Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1\/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis","volume":"80","author":"Zhang","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"21","key":"10.1016\/j.bj.2026.101002_bib12","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"44","key":"10.1016\/j.bj.2026.101002_bib13","doi-asserted-by":"crossref","first-page":"18892","DOI":"10.1073\/pnas.1004952107","article-title":"LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling","volume":"107","author":"Gao","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.bj.2026.101002_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","article-title":"Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics","volume":"19","author":"Yamaguchi","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.bj.2026.101002_bib15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms Controlling PD-L1 Expression in Cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"issue":"7216","key":"10.1016\/j.bj.2026.101002_bib16","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.bj.2026.101002_bib17","first-page":"3659","article-title":"Inactivation of LKB1\/STK11 is a common event in adenocarcinomas of the lung","volume":"62","author":"Sanchez-Cespedes","year":"2002","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.bj.2026.101002_bib18","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/s41388-020-01597-1","article-title":"Cigarette smoke-induced LKB1\/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC","volume":"40","author":"Cheng","year":"2021","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.bj.2026.101002_bib19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrc2676","article-title":"The LKB1-AMPK pathway: metabolism and growth control in tumour suppression","volume":"9","author":"Shackelford","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.bj.2026.101002_bib20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/aps.2012.143","article-title":"Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells","volume":"34","author":"Dong","year":"2013","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"10.1016\/j.bj.2026.101002_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2159-8290.CD-18-0689","article-title":"Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer","volume":"9","author":"Kitajima","year":"2019","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.bj.2026.101002_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cells10113129","article-title":"STK11\/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact","volume":"10","author":"Pons-Tostivint","year":"2021","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.bj.2026.101002_bib23","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.bj.2026.101002_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009444","article-title":"LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer","volume":"12","author":"Lv","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.bj.2026.101002_bib25","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41580-019-0155-x","article-title":"The regulation, functions and clinical relevance of arginine methylation","volume":"20","author":"Guccione","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.bj.2026.101002_bib26","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s12276-021-00613-y","article-title":"Protein arginine methyltransferases: promising targets for cancer therapy","volume":"53","author":"Hwang","year":"2021","journal-title":"Exp Mol Med"},{"issue":"2","key":"10.1016\/j.bj.2026.101002_bib27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1042\/BJ20120768","article-title":"Protein arginine methyltransferase 5 is essential for growth of lung cancer cells","volume":"446","author":"Gu","year":"2012","journal-title":"The Biochemical journal"},{"key":"10.1016\/j.bj.2026.101002_bib28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1746-1596-8-201","article-title":"Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors","volume":"8","author":"Shilo","year":"2013","journal-title":"Diagnostic pathology"},{"issue":"3","key":"10.1016\/j.bj.2026.101002_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.36401\/JIPO-22-1","article-title":"Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review","volume":"5","author":"Feustel","year":"2022","journal-title":"J Immunother Precis Oncol"},{"issue":"18","key":"10.1016\/j.bj.2026.101002_bib30","doi-asserted-by":"crossref","first-page":"9162","DOI":"10.7150\/thno.59605","article-title":"PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression","volume":"11","author":"Jiang","year":"2021","journal-title":"Theranostics"},{"issue":"Pt 1","key":"10.1016\/j.bj.2026.101002_bib31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1042\/BJ20040373","article-title":"Arginine methylation regulates IL-2 gene expression: a role for protein arginine methyltransferase 5 (PRMT5)","volume":"388","author":"Richard","year":"2005","journal-title":"The Biochemical journal"},{"key":"10.1016\/j.bj.2026.101002_bib32","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fimmu.2019.00174","article-title":"PRMT5 Associates With the FOXP3 Homomer and When Disabled Enhances Targeted p185(erbB2\/neu) Tumor Immunotherapy","volume":"10","author":"Nagai","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.bj.2026.101002_bib33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1615\/CritRevImmunol.2020034789","article-title":"PRMT5 and Tip60 Modify FOXP3 Function in Tumor Immunity","volume":"40","author":"Goel","year":"2020","journal-title":"Crit Rev Immunol"},{"issue":"551","key":"10.1016\/j.bj.2026.101002_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5683","article-title":"PRMT5 control of cGAS\/STING and NLRC5 pathways defines melanoma response to antitumor immunity","volume":"12","author":"Kim","year":"2020","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.bj.2026.101002_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011299","article-title":"PRMT5 deficiency in myeloid cells reprograms macrophages to enhance antitumor immunity and synergizes with anti-PD-L1 therapy","volume":"13","author":"Chen","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.bj.2026.101002_bib36","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1124\/mol.112.082743","article-title":"Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor\/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells","volume":"83","author":"Hsia","year":"2013","journal-title":"Molecular pharmacology"},{"issue":"11","key":"10.1016\/j.bj.2026.101002_bib37","article-title":"Co-targeting CDK4\/6 enhances anti-cancer activity and alleviates immune-related adverse events of anti-PD-1 antibody for breast cancer","volume":"6","author":"Hu","year":"2025","journal-title":"Cell Rep Med"},{"issue":"5","key":"10.1016\/j.bj.2026.101002_bib38","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/1878-0261.12193","article-title":"Cigarette smoke enhances oncogene addiction to c\u2010MET and desensitizes EGFR\u2010expressing non\u2010small cell lung cancer to EGFR TKI s","volume":"12","author":"Tu","year":"2018","journal-title":"Molecular oncology"},{"issue":"4","key":"10.1016\/j.bj.2026.101002_bib39","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/jcp.22860","article-title":"Hepatitis B virus X protein induces IKK\u03b1 nuclear translocation via Akt\u2010dependent phosphorylation to promote the motility of hepatocarcinoma cells","volume":"227","author":"Huang","year":"2012","journal-title":"Journal of cellular physiology"},{"key":"10.1016\/j.bj.2026.101002_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177350","article-title":"Targeting protein arginine methyltransferases in breast cancer: Promising strategies","volume":"992","author":"Wei","year":"2025","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.bj.2026.101002_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e22088","article-title":"Pan-cancer analysis identifies protein arginine methyltransferases PRMT1 and PRMT5 and their related signatures as markers associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.bj.2026.101002_bib42","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1186\/s12885-016-2632-3","article-title":"Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation","volume":"16","author":"Sheng","year":"2016","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.bj.2026.101002_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 function and targeting in cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cell Stress"},{"issue":"1","key":"10.1016\/j.bj.2026.101002_bib44","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41420-024-02197-8","article-title":"CircGSK3beta mediates PD-L1 transcription through miR-338-3p\/PRMT5\/H3K4me3 to promote breast cancer cell immune evasion and tumor progression","volume":"10","author":"Liang","year":"2024","journal-title":"Cell Death Discov"},{"issue":"19","key":"10.1016\/j.bj.2026.101002_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e37958","article-title":"CD38 symmetric dimethyl site R58 promotes malignant tumor cell immune escape by regulating the cAMP-GSK3beta-PD-L1 axis","volume":"10","author":"Liang","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bj.2026.101002_bib46","article-title":"PRMT5 Inhibition Promotes PD-L1 Expression and Immuno-Resistance in Lung Cancer","volume":"12","author":"Hu","year":"2021","journal-title":"Front Immunol"},{"issue":"15_suppl","key":"10.1016\/j.bj.2026.101002_bib47","doi-asserted-by":"crossref","first-page":"9028","DOI":"10.1200\/JCO.2018.36.15_suppl.9028","article-title":"Association of STK11\/LKB1 mutations with primary resistance to PD-1\/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC","volume":"36","author":"Skoulidis","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.bj.2026.101002_bib48","article-title":"Protein Arginine Methyltransferase 5 Promotes Esophageal Squamous Cell Carcinoma Proliferation and Metastasis via LKB1\/AMPK\/mTOR Signaling Pathway","volume":"9","author":"Chen","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"issue":"3","key":"10.1016\/j.bj.2026.101002_bib49","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/ijc.31909","article-title":"LKB1 regulates PRMT5 activity in breast cancer","volume":"144","author":"Lattouf","year":"2019","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.bj.2026.101002_bib50","doi-asserted-by":"crossref","DOI":"10.1080\/15412555.2024.2342797","article-title":"FBXL19 Targeted STK11 Degradation Enhances Cigarette Smoke-Induced Airway Epithelial Cell Cytotoxicity","volume":"21","author":"Li","year":"2024","journal-title":"COPD"},{"issue":"12","key":"10.1016\/j.bj.2026.101002_bib51","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/onc.2011.342","article-title":"Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1","volume":"31","author":"Gaude","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.bj.2026.101002_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215594","article-title":"Arginine methyltransferase PRMT5 methylates and destabilizes Mxi1 to confer radioresistance in non-small cell lung cancer","volume":"532","author":"Yang","year":"2022","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bj.2026.101002_bib53","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13046-019-1064-8","article-title":"The arginine methyltransferase PRMT5 and PRMT1 distinctly regulate the degradation of anti-apoptotic protein CFLAR(L) in human lung cancer cells","volume":"38","author":"Li","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bj.2026.101002_bib54","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.apsb.2024.10.016","article-title":"Tumor-intrinsic PRMT5 upregulates FGL1 via methylating TCF12 to inhibit CD8(+) T-cell-mediated antitumor immunity in liver cancer","volume":"15","author":"Sun","year":"2025","journal-title":"Acta Pharm Sin B"}],"container-title":["Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417026000582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417026000582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:33:53Z","timestamp":1787729633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2319417026000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":54,"alternative-id":["S2319417026000582"],"URL":"https:\/\/doi.org\/10.1016\/j.bj.2026.101002","relation":{},"ISSN":["2319-4170"],"issn-type":[{"value":"2319-4170","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PRMT5-mediated methylation of LKB1 controls PD-L1 expression in NSCLC","name":"articletitle","label":"Article Title"},{"value":"Biomedical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bj.2026.101002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chang Gung University.","name":"copyright","label":"Copyright"}],"article-number":"101002"}}